Bone, fracture and frailty

Curr Opin HIV AIDS. 2011 Jul;6(4):309-14. doi: 10.1097/COH.0b013e3283478741.

Abstract

Purpose of review: This review details recent findings from cohort studies that inform the prevalence, incidence and effects of antiretroviral therapy (ART) and HIV infection on low bone mineral density (BMD), osteoporosis and fractures in different populations of HIV-infected individuals. Although ART has been spectacularly effective in prevention of disease progression and improvement in survival, the effects of ART on bone health require more research.

Recent findings: Both HIV infection and ART are associated with significant bone loss in HIV-infected individuals. The clinical consequence of low BMD, fragility fractures are more common in older HIV patients, but the significance of low BMD remains unclear in younger individuals. Vitamin D deficiency is common, but the prevalence is no different to the general population, and no effect on BMD has been noted in cross-sectional studies. Frailty occurs at a prevalence of about 10% and is related to impaired immunity.

Summary: This review examines the contributions from recent cohort studies to the understanding of the pathogenesis of bone loss in HIV, and the complex and poorly understood relationship between the effects of HIV and that of ART on bone loss.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / adverse effects*
  • Bone Resorption / chemically induced
  • Bone and Bones / drug effects*
  • Bone and Bones / pathology
  • Cohort Studies
  • Fractures, Bone / chemically induced*
  • Fractures, Bone / epidemiology*
  • Fractures, Bone / pathology
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • Humans
  • Incidence
  • Prevalence

Substances

  • Anti-HIV Agents